drugset / Trial / NCT06500234

Nutrition Impact on Immunotherapy of Cancer

NCT06500234

Phase 3 Recruiting 300 enrolled Qingdao Central Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study investigates nutritional status and outcomes of immuntherapy in cancer patients.

Timeline

Start
2024-06-01
Primary completion
2025-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 160 mg Oral
Subject Olanzapine Small molecule 2.5 mg Oral